Phaseline

Companies › Zhejiang Sunshine Mandi Pharmaceutical

Zhejiang Sunshine Mandi Pharmaceutical: clinical trials, targets and expected readouts

2 active drug programs in 5 registered trials: 2 Phase 3, 2 Phase 2, 1 Phase 1; Immunology; next expected readout Dec 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Minoxidil
Sulfonylurea receptor 2, Kir6.2 opener
Ion channels, ABCC9Phase 3Androgenetic AlopeciaDec 2027
Clascoterone
Androgen Receptor antagonist
ARPhase 3Acne Vulgaris; Papular-pustular Rosacea; Pilonidal Disease–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06952517ClascoteronePhase 2Papular-pustular RosaceaImmunologySep 2025
NCT05891795ClascoteronePhase 1Acne VulgarisImmunologyJan 2026
NCT06403501ClascoteronePhase 3Acne VulgarisImmunologyOct 2026
NCT07080931MinoxidilPhase 3Androgenetic AlopeciaImmunologyDec 2027
NCT06286397ClascoteronePhase 2Pilonidal DiseaseImmunologyJan 2028

Targets

AR (1) Ion channels (1) ABCC9 (1)

Companies with the same targets

Johnson & Johnson (Janssen) Novartis Astellas Jiangsu HengRui Medicine Alessa Therapeutics Sun Pharmaceutical Industries Xenon Pharmaceuticals Industrial Farmacéutica Cantabria Praxis Precision Medicines Hansoh BioMedical R&D Company

Companies built like this

Industrial Farmacéutica Cantabria Biopharma Plasma Psoriasis Research Institute of Guangzhou KalVista Pharmaceuticals Triple Hair

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.